Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
See Latest ArticlesLonger Wait Times Increase Overall Mortality in Patients With Bladder Cancer
The Journal of Urology, 09/25/09
Kulkarni GS et al. – Treatment delay between transurethral bladder tumor resection and radical cystectomy resulted in worse overall survival. The effect of wait time was greatest in lower stage lesions. The suggested maximum wait time from transurethral bladder tumor resection to cystectomy was 40 days. Further studies assessing disease–free survival are required to corroborate these findings.
Related Articles
High frequency of tumor cells with nuclear Egr-1 protein expression in human bladder cancer is associated with disease progression
BMC Cancer, 11/13/09
Relevance Score: 70%
Evidence-based Principles of Bladder Cancer and Diet
Urology, 10/21/09
Relevance Score: 70%
Incidence analyses of bladder cancer in the Nile delta region of Egypt
Cancer Epidemiology, 10/20/09
Relevance Score: 70%
Biomarkers in bladder cancer
BJU International, 10/01/09
Relevance Score: 70%
Diagnosis and Treatment of Bladder Cancer
American Family Physician, 10/01/09
Relevance Score: 70%
Today in Bladder...keeping you current
Receive free subspecialty "5-minute updates" via email
Is there a learning curve for subureteric injection of dextranomer/hyaluronic acid in the treatment of vesicoureteral reflux?
Journal of Pediatric Urology , 03/19/10
Postnatal outcome of fetal hydronephrosis: Implications for prenatal counselling
Indian Journal of Urology, 03/18/10
Protein expression and gene promoter hypermethylation of CD99 in transitional cell carcinoma of urinary bladder
Journal of Cancer Research & Clinical Oncology, 03/18/10
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer: double tubulin targeting
Internal Medicine Journal, 03/19/10
DNA methylation of HOXD3 as a marker of prostate cancer progression
Laboratory Investigation, 03/19/10
Emerging Role of microRNAs in Prostate Cancer: Implications for Personalized Medicine
Discovery Medicine, 03/19/10
Article Search
Sponsor